Trailing-twelve-month (TTM) revenue is $766.29 Million with a year-over-year growth of +11.19%. Revenue represents the total income generated from the company's primary business operations.
Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.
| Fiscal period | Revenue | Source |
|---|---|---|
| Q3 FY2025Period ended 2025-09-30 | $187,797,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-10-28 |
| Q4 FY2025Period ended 2025-12-31 | $190,170,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-02-17 |
| Q1 FY2026Period ended 2026-03-31 | $186,672,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-04-28 |
| Q2 FY2026Period ended 2026-06-30 | $201,656,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-07-28 |
| TTM revenue | $766,295,000 |
Current P/S: $470,346,975 market capitalization ÷ $766,295,000 TTM revenue = 0.61x.
Market capitalization source: FMP quote. Quote observed 2026-10-02T19:05:12.000Z. Latest revenue period ended 2026-06-30.
Current market capitalization comes from the quote provider. EPS weighted-average shares are a separate measure.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
Reported quarterly revenue; no daily interpolation. Q2 FY2026 (2026-06-30): $201.66M.
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters Quote observation: 2026-10-02T19:05:52.185Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-10-01.
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
FMP selected disclosures by reporting period. Rows match exact source labels; they may overlap. N/A means no matching disclosure, not zero. Filing links identify reviewed presentation labels for that period.
| FMP source label (unverified unless linked) | FY20202020-12-31 · USD | FY20212021-12-31 · USD | FY20222022-12-31 · USD | FY20232023-12-31 · USD | FY20242024-12-31 · USD | FY20252025-12-31 · USD |
|---|---|---|---|---|---|---|
| Clinical Services | $382M | $404M | $419M | $496M | N/A | N/A |
| Commercial Insurance | N/A | N/A |
$766.29M
$766.29 Million
+11.19%
vs. $689.18M a year ago (TTM)
+9.41%
5 Year compound annual growth rate
1 Year
+11.19%
3 Year
+11.58%
5 Year
+9.41%
10 Year
+15.90%
15 Year
+22.45%
20 Year
+29.40%
CAGR shows the annualized growth rate over the specified period, smoothing out year-to-year volatility.
| Year | Revenue | YoY Change | % Change |
|---|---|---|---|
| 2025 | $727.33M | +$66.77M | +10.11% |
| 2024 | $660.57M | +$68.92M | +11.65% |
| 2023 | $591.64M | +$81.92M | +16.07% |
| 2022 | $509.73M | +$25.40M | +5.24% |
| 2021 | $484.33M | +$39.88M | +8.97% |
| 2020 |
TTM Growth
+11.19%
3-Year CAGR
+11.58%
5-Year CAGR
+9.41%
Revenue growth vs the same fiscal quarter in the prior fiscal year, last 40 comparable quarters.
Current FMP quote-based enterprise value / four-quarter revenue Quote observation: 2026-10-02T19:05:52.185Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-10-01.
| N/A |
| $100M |
| $118M |
| Pharma Services | $62M | $80M | $91M | N/A | N/A | N/A |
|---|
| $444.45M |
| +$35.62M |
| +8.71% |
| 2019 | $408.83M | +$132.09M | +47.73% |
| 2018 | $276.74M | +$36.49M | +15.19% |
| 2017 | $240.25M | ($3.83M) | (1.57%) |
| 2016 | $244.08M | +$144.28M | +144.57% |
